Brief Report: Anti-phospholipid antibodies in critically ill patients with Coronavirus Disease 2019 (COVID-19)

Meng Xiao*, M.S., Yan Zhang*, M.D., Shulan Zhang*, M.D., Xuzhen Qin*, M.D., Peng Xia†, M.D., Wei Cao†, M.D., Wei Jiang†, M.D., Huan Chen†, M.D., Xin Ding†, M.D., Hua Zhao†, M.D., Hongmin Zhang†, M.D., Chunyao Wang†, M.D., Jing Zhao†, M.D., Xuefeng Sun†, M.D., Ran Tian†, M.D., Wei Wu†, M.D., Dong Wu†, M.D., Jie Ma†, M.D., Yu Chen†, B.S., Dong Zhang†, M.S., Jing Xie†, Ph.D., Xiaowei Yan†, M.D., Xiang Zhou†, M.D., Zhengyan Liu†, M.D., Jinglan Wang†, M.D., Bin Du†, M.D., Yan Qin†, M.D., Peng Gao†, M.D., Minya Lu†, M.D., Xin Hou†, Ph.D., Xian Wu†, Ph.D., Huadong Zhu†, M.D., Yingchun Xu†, M.D., Wen Zhang†, M.D., Taisheng Li†, M.D., Fengchun Zhang†, M.D., Yongqiang Zhao*, M.D., Yongzhe Li*#, M.D., Shuyang Zhang*#, M.D.

*These authors contributed equally to the study.
#These authors contributed equally as senior authors.

1Department of Laboratory Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, 100730

2Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, 100730

This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as doi: 10.1002/art.41425

This article is protected by copyright. All rights reserved
Sciences, Beijing, 100730

3Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, 100730

4Department of Nephrology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, 100730

5Department of Infectious Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, 100730

6Department of Medical ICU, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, 100730

7Department of Intensive care Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, 100730

8Department of Pulmonary and Critical Care, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, 100730

9Department of Cardiology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, 100730

10Department of Gastroenterology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, 100730

11Department of Emergency Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, 100730

**Correspondence:** Shuyang Zhang, Department of Cardiology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, 1# Shuai Fu Yuan, Beijing 100730 China. Phone: +86-10-69156810. E-mail: shuyangzhang103@163.com.

or Yongzhe Li, Department of Laboratory Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, 1# Shuai Fu Yuan, Beijing 100730 China. Phone: +86-10-69159713.
Subtitle: aPLs in Critically Ill Patients With COVID-19

Funding This research was supported by grants from CAMS Innovation Fund for Medical Sciences (CIFMS) (2020-I2M-CoV19-001, 2017-I2M-3-001 and 2017-I2M-B&R-01), the National Natural Science Foundation of China Grants (81671618, 81871302).

Word Count: 1827
Abstract

Objectives: Coagulopathy is one of the characteristics of critically ill patients with Coronavirus Disease 2019 (COVID-19). Antiphospholipid antibodies (aPLs) contribute to coagulopathy, but their role in COVID-19 remains unclear. We aimed to determine the prevalence and characteristics of aPLs in patients with COVID-19.

Methods: Sera collected from 66 critically ill and 13 non-critically ill patients with COVID-19 were tested for anti-cardiolipin (aCL) and anti-β2-glycoprotein 1 (aβ2GP1) (IgG, IgM, and IgA) and IgG aβ2GP1-D1 by the chemiluminescence assay (CIA) and IgM and IgG anti-phosphatidylserine/prothrombin (aPS/PT) by ELISA.

Results: aPLs were detected in 47.0% of critically ill patients (31/66), but not in patients with non-critical conditions. IgA aβ2GP1 was the most common aPL, present in 28.8% (19/66) critically ill patients, followed by IgA aCL (25.8%, 17/66) and IgG aβ2GP1 (18.2%, 12/66). For multiple aPLs, IgA aβ2GP1+IgA aCL was the most common type (22.7%, 15/66), followed by IgA aβ2GP1+IgA aCL+IgG aβ2GP1 (15.2%, 10/66). aPLs emerge around 35-39 days post-disease onset. Dynamic analysis of aPLs revealed 4 patterns based on persistence or transient appearance of the aPLs. Patients with multiple aPLs displayed significantly higher incidence of cerebral infarction (p=0.023).

Conclusions: aPLs were common in critically ill patients. Multiple medium or high levels aPLs may help identify patients at risk of developing cerebral infarction. aPLs may be transient and disappear within a few weeks, but in genetically predisposed patients, COVID-19 may trigger the development of “COVID-19-induced-APS-like-syndrome”. Long-term follow-up on COVID-19 patients positive for aPLs would be of great importance.

Keywords: COVID-19, antiphospholipid antibodies, coagulopathy, critically ill patients,
We and others have observed that critically ill patients with Coronavirus Disease 2019 (COVID-19) are associated with a proinflammatory and hypercoagulable state and increased risk of thrombotic events (i.e., pulmonary embolism and cerebral infarction), which are characterized by marked elevations of D-dimers (1-6). Currently, the etiology leading to hypercoagulability in COVID-19 remains unclear. Antiphospholipid syndrome (APS), an autoimmune disorder characterized by the presence of antiphospholipid antibodies (aPLs) and a wide series of clinical manifestations, from recurrent arterial and/or venous thrombotic events to recurrent fetal loss. aPLs have long been considered as one of the contributors to the hypercoagulable states and following thrombotic events. In addition to the pathogenic role in APS, aPLs are crucial to the diagnosis of APS. The 2006 criteria recommend lupus anticoagulant (LA), IgM and/or IgG anti-cardiolipin (aCL) and IgM and/or IgG anti-β2-glycoprotein 1 (aβ2GP1) antibodies for routine tests. In addition, 14th International Congress on Antiphospholipid Antibodies Technical Task Force Report highlighted non-criteria aPLs, including IgA aCL, IgA aβ2GP1, IgM/IgG anti-phosphatidylserine/prothrombin (aPS/PT) and aβ2GP1 domain 1 (D1), are associated to the APS, especially seronegative APS (SNAPS) (7, 8). We have previously reported the presence of aPLs in 3 critically ill patients with COVID-19 (9). However, it remains unclear whether these aPLs are pathogenic or whether they are persistent. In this study, we summarize the prevalence and characteristics of aPLs in 66 critically ill patients with COVID-19 and provide clinical features based on the presence of aPLs.

Materials

Settings and Patients

Consecutive critically ill patients with suspected COVID-19, who were admitted to an intensive care unit (ICU) designated for patients with COVID-19, were included in this cross-sectional study. This unit, which was managed by a multidisciplinary team from Peking Union Medical College Hospital
(PUMCH) in the Sino-French New City Branch of Tongji Hospital in Wuhan, China, was set up on an emergency basis to accept the most critically ill patients during the outbreak of COVID-19. Patients inclusion criteria were all the patients managed in our ICU. Patients exclusion criteria were: 1). non-COVID-19 patients; 2). COVID-19 patients who did not test for aPLs. A total of 66 critically ill patients with COVID-19 were finally included in this study. COVID-19 patients visiting the fever clinic in PUMCH in Beijing, China, were also included. The inclusion criteria for those patients were all the consecutive patients who visited our fever clinic in PUMCH in Beijing. Exclusion criteria were non-COVID-19 patients. A total of 13 patients with COVID-19 were finally included. All these 13 patients were non-critically ill patients. The diagnosis of SARS-CoV-2 infection was confirmed in all the patients by reverse-transcriptase-polymerase-chain-reaction (RT-PCR) assay or serologic testing according to the Chinese Recommendations for Diagnosis and Treatment of Novel Coronavirus Infection (Pilot 7th version). The clinical characteristics and laboratories parameters at time of admission, which were collected from electronic medical records, are listed in Table 1. The study was approved by the Research Ethics Commission of PUMCH and the requirement for informed consent was waived by the Ethics Commission (ZS-2303).

**Serum aPLs Determination**

Serum aCL and aβ2GP1 (IgG, IgM, and IgA) and IgG aβ2GP1-D1 were determined by the chemiluminescence assay (CIA) (INOVA)(10). The cutoff values for positivity were set >20 U based on manufacturer’s recommendations. IgG/IgM aPS/PT were determined by ELISA (INOVA)(11). The cutoff values for positivity were set >30 U based on manufacturer’s recommendations.

**Lupus anticoagulant (LA)**

The detection of LA in human citrated plasma was performed by the HemosIL dRVVT Screen and HemosIL dRVVT Confirm assays, as recommended by the International Society on Thrombosis and Haemostasis (ISTH).

**Statistical analysis**
Mann-Whitney U test, χ² test, or Fisher’s exact test were utilized to compare differences between aPL positive group and aPL negative group where appropriate. A Kruskal-Wallis test followed by Dunnett's T2 test was used to compare aPLs negative group, Single/multiple group and Multiple group. A two-sided α of less than 0.05 was considered statistically significant. Statistical analyses were performed on SPSS 20.0 package (SPSS Inc.).

Results

We first determined the prevalence and characteristics of aPLs in patients with COVID-19. When the manufacturer’s recommended cut-off value of >20 CU was utilized, aPLs were detected in 47.0% of critically ill patients (31/66), but not in patients with non-critical conditions (Table 2). Previous study has shown that moderate to high titers of aPLs display better clinical significance (12). As such, we re-analyzed the prevalence of aPLs utilizing the cut-off value of >40 CU. aPLs were present in 31.8% of critically ill patients (21/66). We next assessed the prevalence of each aPL. For single aPL, IgA aβ2GP1 was the most common type of aPLs, present in 28.8% (19/66) of critically ill patients and 61.3% (19/31) of aPLs-positive patients, respectively, followed by IgA aCL (25.8% (17/66) and 54.8% (17/31), respectively), and IgG aβ2GP1 (18.2% (12/66) and 38.7% (12/31), respectively). For multiple aPLs, IgA aβ2GP1+IgA aCL was the most common type (22.7%, 15/66), followed by IgA aβ2GP1+IgA aCL+ IgG aβ2GP1 (15.2%, 10/66) and IgA aCL+IgG aCL+IgA aβ2GP1+IgG aβ2GP1 (6.1%, 4/66). Lupus anticoagulant was tested in all the 66 critically-ill patients, among whom, LA was positive in 2 patients. These findings suggested that COVID-19 preferentially induced IgA isotype aPLs and to a less extent, the IgG isotype aPLs.

Next, we determined when the aPLs emerged in those patients. Among the 31 aPL-positive patients, we had sera from 10 patients who were negative for aPLs at early time-point and positive for aPLs at
later time-point. Analysis of those patients revealed that aPLs emerged around a median time of 39 days post-disease onset (Supplemental table 1). Taken together, these findings show that aPLs emerge at a later time-point, suggesting critically ill patients with longer disease duration are likely to have aPLs.

Dynamic changes in the levels of aPLs during COVID-19 in critically ill patients were further investigated. Due to the retrospective nature, multiple time-points of aPLs results were only obtained from 6 patients (Figure 1). Generally, the levels and types of aPLs increased from a single type with low titers to multiple types with high titers. For the later time-points, those 6 patients exhibited different patterns. In patient 1, medium levels of IgG aβ2GP1 were maintained despite interventions with plasma exchanges (Figure 1A). In patients 2 and 3, medium levels of IgA aβ2GP1+IgA aCL were maintained after a transient appearance of IgG aβ2GP1 (Figure 1B). In patients 4 and 5, the aPLs were transient and disappeared at later time-points (Figure 1C). In patient 6, high levels of IgA aCL+IgA aβ2GP1+IgG aβ2GP1 were maintained for around two weeks (Figure 1D). These results suggest that the levels of aPLs are fluctuated and exhibit different dynamic patterns among different patients during COVID-19.

Last, we assessed the clinical relevance of aPLs in critically ill patients with COVID-19 (Table 1). As mounting evidence suggest that multiple aPL positivity or moderate to high titers of aPLs display better clinical values compared to single aPL positivity or low titers of aPLs. We divided aPLs positive group into single/multiple\textsuperscript{lo} group (patients positive for single aPL or positive for more than one aPLs but the values of all aPLs was at low titers (<=40 CU), as previously described (13)) and multiple\textsuperscript{med/hi} group (patients positive for more than one aPLs and the value of at least one aPL was at moderate titers (>40 CU)). The three critically ill groups displayed similar clinical and laboratory features, but the multiple\textsuperscript{med/hi} group showed significantly higher incidence of cerebral infarction compared to
aPL-negative group (0 vs 33.3%, \( p=0.023 \)), suggesting that aPLs may be helpful in predicting the occurrence of cerebral infarction during COVID-19.

**Discussion**

The full spectrum of COVID-19 is still under intense investigation, but increasing evidence suggest that most critically ill patients suffer from coagulopathy (1-3). aPLs have been considered as one of the mechanisms leading to a proinflammatory and hypercoagulable state. In this study, we found that aPLs were present in a substantial number of critically ill patients. Although it remains unclear whether aPLs contribute to the hypercoagulable state in COVID-19, our findings suggest a possibility that aPLs may be implicated in this process.

Infection-induced aPL production has been widely acknowledged (14, 15). Of particular interest is that we found IgA, an isotype specialized in mucosal immunity, was the most common aPLs isotype. As COVID-19 mainly affects pulmonary and intestinal mucosa, the preferential production of IgA isotype may be associated with the breakage of mucosal immune tolerance. IgA αβ2GPI preferentially target the C-terminal portion of β2GPI (domain 4 and 5) (16), thus the presence of IgA aPLs may suggest a novel subgroup of clinically relevant APS in critically ill patients with COVID-19. Interestingly, we found that although IgA aCL and IgA αβ2GPI transiently appeared in a subgroup patient, they persisted in another subgroup patients. Unfortunately, we could not perform long-term follow-up. A prospective evaluation of those aPLs in COVID-19 patients is in great need to investigate whether these are persistent and pathogenic or require long-term anticoagulants.

While it remains unclear whether IgA aPLs are pathogenic in APS, *in vivo* mouse studies demonstrated that IgA αβ2GPI induced significantly larger thrombi and higher tissue factor (TF) levels.
compared to controls (17). IgA aβ2GPI are significantly and independently associated with arterial thrombosis and all thrombosis in patients with systemic lupus erythematosus (SLE) and APS (17). In addition, IgA aβ2GPI has been described as an independent risk factor for acute myocardial infarction (16, 18) and acute cerebral ischaemia (19). In this study, we found that patients with multiple aPLs, including IgA and IgG aβ2GPI and IgA and IgG aCL, displayed significantly higher incidence of cerebral infarction. Unfortunately, due to the critical condition of those patients as well as the limitation of the isolation ward, a large number of patients could not be screened by ultrasound, thus many thrombotic events may be underrepresented. It is also worth mentioning that the patients who developed cerebral infarction may have already had atherosclerosis and aPLs. It would be of great interest to assess whether multiple medium or high levels aPLs may help identify patients at risk of developing cerebral infarction in critically ill patients with COVID-19 in future studies.

This study has several limitations. In the analysis of the time-point for the emergence of aPLs, due to the retrospective nature of this study, for some patients, we only had one time-point, and for other patients, although we had more than one time-points, aPLs were already positive in the early time-point. Thus, we ended up with only 10 patients for the following analysis. The small sample size may bring analytical bias. Further prospective studies on the time-point of the emergence of aPLs are needed.

In conclusion, clinical significance of aPLs in critically ill patients with COVID-19 remains to be determined. In some patients, transient rises in aPL may be accompanied by thrombotic complications (15). It is worthy to note that, although in some patients, these antibodies may be transient and disappear within a few weeks, in other genetically predisposed patients, COVID-19 may trigger the development of “COVID-19-induced-APS-like-syndrome”. Long-term follow-up on COVID-19 patients positive for aPLs would be of great importance.
Acknowledgements

Dr. Shuyang Zhang has received support from CAMS Innovation Fund for Medical Sciences (CIFMS) (No. 2020-I2M-CoV19-001). Dr. Yongzhe Li has received support from CAMS Innovation Fund for Medical Sciences (CIFMS) (2017-I2M-3-001, 2017-I2M-B&R-01). Dr. Yongzhe Li has received support from the National Natural Science Foundation of China Grants (81671618, 81871302). Dr. Shulan Zhang has received support from CAMS Innovation Fund for Medical Sciences (CIFMS) (2017-I2M-3-001).

Conflicts of Interest

The authors declare no competing financial interests.
Figures

Figure 1. Dynamic changes in the levels of aPLs during COVID-19 infection in critically ill patients (A). Patient 1, medium levels of IgG aβ2GP1 persisted after a transient appearance of IgA aβ2GP1+IgA aCL. (B). Patient 2 (left panel) and patient 3 (right panel), medium levels of IgA aβ2GP1+IgA aCL persisted after a transient appearance of IgG aβ2GP1. (C). Patient 4 (left panel) and patient 5 (right panel), transient appearance of aPLs. (D). Patient 6, high levels of IgA aCL+IgA aβ2GP1+IgG aβ2GP1 persisted.

References

1. Li T, Lu H, Zhang W. Clinical observation and management of COVID-19 patients. Emerg Microbes Infect. 2020;9(1):687-90.
2. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054-62.
3. Han H, Yang L, Liu R, Liu F, Wu KL, Li J, et al. Prominent changes in blood coagulation of patients with SARS-CoV-2 infection. Clin Chem Lab Med. 2020.
4. Dolhnikoff M, Duarte-Neto AN, de Almeida Monteiro RA, Ferraz da Silva LF, Pierre de Oliveira E, Nascimento Saldiva PH, et al. Pathological evidence of pulmonary thrombotic phenomena in severe COVID-19. J Thromb Haemost. 2020.
5. Bikdeli B, Madhavan MV, Jimenez D, Chuich T, Dreyfus I, Driggin E, et al. COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-up. J Am Coll Cardiol. 2020.
6. Tavazzi G, Civardi L, Caneva L, Mongodi S, Mojoli F. Thrombotic events in SARS-CoV-2 patients: an urgent call for ultrasound screening. Intensive Care Med. 2020.
7. Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006;4(2):295-306.

8. Abreu MM, Danowski A, Wahl DG, Amigo MC, Tektonidou M, Pacheco MS, et al. The relevance of "non-criteria" clinical manifestations of antiphospholipid syndrome: 14th International Congress on Antiphospholipid Antibodies Technical Task Force Report on Antiphospholipid Syndrome Clinical Features. Autoimmun Rev. 2015;14(5):401-14.

9. Zhang Y, Xiao M, Zhang S, Xia P, Cao W, Jiang W, et al. Coagulopathy and Antiphospholipid Antibodies in Patients with Covid-19. N Engl J Med. 2020.

10. Zhang S, Wu Z, Chen S, Li J, Wen X, Li L, et al. Evaluation of the diagnostic potential of antibodies to beta2-glycoprotein 1 domain 1 in Chinese patients with antiphospholipid syndrome. Sci Rep. 2016;6:23839.

11. Zhang S, Wu Z, Zhang W, Zhao J, Norman GL, Zeng X, et al. Antibodies to phosphatidylserine/prothrombin (aPS/PT) enhanced the diagnostic performance in Chinese patients with antiphospholipid syndrome. Clin Chem Lab Med. 2018;56(6):939-46.

12. Ordi-Ros J, Saez-Comet L, Perez-Conesa M, Vidal X, Riera-Mestre A, Castro-Salomo A, et al. Rivaroxaban Versus Vitamin K Antagonist in Antiphospholipid Syndrome: A Randomized Noninferiority Trial. Ann Intern Med. 2019;171(10):685-94.

13. Ordi-Ros J, Saez-Comet L, Perez-Conesa M, Vidal X, Riera-Mestre A, Castro-Salomo A, et al. Rivaroxaban Versus Vitamin K Antagonist in Antiphospholipid Syndrome: A Randomized Noninferiority Trial. Ann Intern Med. 2019.

14. Mendoza-Pinto C, Garcia-Carrasco M, Cervera R. Role of Infectious Diseases in the Antiphospholipid Syndrome (Including Its Catastrophic Variant). Curr Rheumatol Rep. 2018;20(10):62.

15. Asherson RA, Cervera R. Antiphospholipid antibodies and infections. Ann Rheum Dis.
16. Andreoli L, Fredi M, Nalli C, Piantoni S, Reggia R, Dall'Ara F, et al. Clinical significance of IgA anti-cardiolipin and IgA anti-beta2glycoprotein I antibodies. Curr Rheumatol Rep. 2013;15(7):343.

17. Murthy V, Willis R, Romay-Penabad Z, Ruiz-Limon P, Martinez-Martinez LA, Jatwani S, et al. Value of isolated IgA anti-beta2 -glycoprotein I positivity in the diagnosis of the antiphospholipid syndrome. Arthritis Rheum. 2013;65(12):3186-93.

18. Ranzolin A, Bohn JM, Norman GL, Manenti E, Bodanese LC, von Muhlen CA, et al. Anti-beta2-glycoprotein I antibodies as risk factors for acute myocardial infarction. Arq Bras Cardiol. 2004;83(2):141-4; 37-40.

19. Staub HL, Norman GL, Crowther T, da Cunha VR, Polanczyk A, Bohn JM, et al. Antibodies to the atherosclerotic plaque components beta2-glycoprotein I and heat-shock proteins as risk factors for acute cerebral ischemia. Arq Neuropsiquiatr. 2003;61(3B):757-63.
Table 1. Demographic, clinical characteristics and laboratory findings of patients infected with COVID-19

| Characteristics                              | Critically-ill (n=66) | Non-critically-ill (n=13) | p-value |
|-----------------------------------------------|-----------------------|---------------------------|---------|
|                                              | aPLs negative (n=35)  | aPLs positive (n=31)      |         |
|                                              | Single/multiple (n=16)| Multiple^med/hi (n=15)    |         |
| Age, years                                   | 64.5±12.3             | 66.5±13.3                 | 0.850   |
| Gender, female/male                          | 17/18                 | 5/11                      | 0.402   |
| Comorbidity                                  |                       |                           |         |
| Hypertension, n (%)                          | 17 (48.6)             | 8 (50.0)                  | 0.953   |
| Diabetes, n (%)                              | 6 (17.1)              | 3 (18.8)                  | 0.657   |
| Coronary heart disease, n (%)                | 8 (22.9)              | 0                         | 0.092   |
| Lung disease, n (%)                          | 5 (14.3)              | 1 (6.2)                   | 0.660   |
| Carcinoma, n (%)                             | 1 (2.9)               | 1 (6.2)                   | 0.247   |
| Chronic kidney disease, n (%)                | 0                     | 0                         | N/A     |
| Chronic liver disease, n (%)                 | 4 (11.4)              | 0                         | 0.499   |
| Autoimmune diseases, n (%)                   | 2 (5.7)               | 0                         | 1.000   |
| Thrombotic history                           |                       |                           |         |
| Cerebral infarction, n (%)                   | 4 (11.4)              | 3 (18.8)                  | 0.889   |
| Myocardial infarction, n (%)                 | 1 (2.9)               | 1 (6.2)                   | 0.723   |
| Other thrombotic events                      | 0                     | 0                         | N/A     |
| Symptoms on admission                        |                       |                           |         |
| Fever (temperature ≥37.3°C), n (%)           | 31 (88.6)             | 14 (87.5)                 | 1.000   |
| Cough, n (%)                                 | 32 (91.4)             | 12 (75.0)                 | 0.079   |
| Sputum, n (%)                                | 12 (34.3)             | 6 (37.5)                  | 0.885   |
| Dyspnea, n (%)                               | 28 (80.0)             | 15 (93.8)                 | 0.336   |
| Myalgia, n (%)                               | 9 (25.7)              | 4 (25.0)                  | 1.000   |
| Fatigue, n (%)                               | 15 (42.9)             | 3 (18.8)                  | 0.116   |
| Diarrhoea, n (%)                             | 12 (34.3)             | 3 (18.8)                  | 0.271   |
| Headache, n (%)                              | 6 (17.1)              | 2 (12.9)                  | 0.911   |
| Nausea or vomiting, n (%)                    | 9 (25.7)              | 1 (6.2)                   | 0.276   |
| Disease severity status                      |                       |                           |         |
| General, n (%)                               | 0                     | 0                         | 12 (92.3)|
| Severe, n (%)                                | 0                     | 0                         | 1 (7.7) |
| Critical, n (%)                              | 35 (100)              | 16 (100)                  | 0.794   |
| ARDS, n (%)                                  | 12 (34.3)             | 7 (43.8)                  | 0.516   |
| Respiratory failure, n (%)                   | 23 (65.7)             | 13 (81.2)                 | 0.921   |
| Laboratory findings on admission             |                       |                           |         |
| White blood cell count, 10^9/L               | 13.5±6.3              | 14.3±7.1                  | 7.3±2.4 |
| Total neutrophil count, 10^9/L               | 12.1±5.9              | 12.1±6.8                  | 3.3±1.6 |
| Test                        | Value             | Value             | Value             | Value             | Value             |
|-----------------------------|-------------------|-------------------|-------------------|-------------------|-------------------|
| Total lymphocyte count, 10^9/L | 0.6±0.6          | 0.8±0.6          | 0.7±0.4          | 0.599             | 1.7±0.7          |
| Red blood cell count, 10^{12}/L | 3.5±0.9          | 4.1±1.2          | 3.5±0.6          | 0.130             | 4.5±0.6          |
| Platelets, 10^9/L           | 150.6±102.9      | 177.9±83.9       | 185.0±83.2       | 0.419             | 223.0±62.8       |
| Hemoglobin, g/L             | 108.5±23.7       | 120.8±28.3       | 107.3±22.2       | 0.211             | 134.1±14.8       |
| ALT, U/L                    | 38.1±64.2        | 68.4±156.7       | 28.9±19.5        | 0.456             | 14.2±7.5         |
| AST, U/L                    | 37.8±30.7        | 180.4±583.7      | 34.0±18.7        | 0.224             | N.D.             |
| LDH, U/L                    | 510.1±292.9      | 533.6±458.8      | 447.9±218.5      | 0.750             | N.D.             |
| Hemoglobin µmol/L           | 106.6±125.9      | 74.6±40.5        | 76.3±37.2        | 0.427             | 52.3±23.5        |
| eGFR (ml/min/1.73m^2)       | 83.0±35.0        | 89.8±31.7        | 86.9±24.8        | 0.770             | N.D.             |
| High-sensitive cardiac troponin I, pg/ml | 594.9±2410.0 | 607.0±1921.2 | 215.7±497.6 | 0.812 | N.D. |
| NT-proBNP, pg/ml            | 3029.6±5306.6    | 1756.2±2189.2    | 2016.9±2217.6    | 0.536             | N.D.             |
| Prothrombin time, s         | 17.6±3.5         | 17.6±7.5         | 16.1±1.0         | 0.561             | N.D.             |
| APTT, s                     | 45.4±21.0        | 45.8±7.6         | 41.36±6.44       | 0.677             | N.D.             |
| Fibrinogen, g/L             | 3.6±2.1          | 4.8±1.6          | 4.5±1.2          | 0.064             | N.D.             |
| D-dimer, µg/L               | 10.9±8.8         | 10.2±9.0         | 8.9±7.6          | 0.744             | N.D.             |
| Procalcitonin, ng/mL        | 0.8±1.9          | 0.3±0.4          | 1.2±2.0          | 0.335             | 0.2±0.1          |
| hsCRP, mg/L                 | 88.7±84.3        | 98.1±57.6        | 99.5±51.8        | 0.855             | N.D.             |
| IL-6, pg/ml                 | 289.5±877.5      | 277.3±539.1      | 103.1±125.3      | 0.671             | N.D.             |

**Treatments**

| Treatment                                | n (%)  | n (%)  | n (%)  | p-Value | N/A |
|------------------------------------------|--------|--------|--------|---------|-----|
| Corticosteroids, n (%)                   | 27     | 12     | 10     | 0.703   | N/A |
| Intravenous immunoglobin, n (%)          | 18     | 8      | 11     | 0.325   | N/A |
| Non-invasive mechanical ventilation, n (%) | 17    | 11     | 7      | 0.348   | N/A |
| Invasive mechanical ventilation, n (%)   | 28     | 14     | 15     | 0.193   | N/A |
| Anticoagulant therapy, n (%)             | 19     | 12     | 9      | 0.372   | N/A |
| ECMO, n (%)                              | 3      | 1      | 3      | 0.490   | N/A |

**Thrombotic events during COVID-19 infection**

| Event                              | n (%)  | n (%)  | n (%)  | p-Value | N/A |
|------------------------------------|--------|--------|--------|---------|-----|
| Arterial thrombosis                | 0      | 0      | 5      | 0.010   | 0   |
| Myocardial infarction              | 0      | 0      | 1      | 0.227   | 0   |
| Venous thrombosis                  | 0      | 0      | 2      | 0.227   | 0   |
| Large vein                         | 10     | 3      | 4      | 0.870   | 0   |
| Distal Vein                        |        |        |        |         |     |

ALT, alanine transaminase; aPLs, Antiphospholipid antibodies; APTT, activated partial thromboplastin time; ARDS, acute respiratory distress syndrome; AST, aspartate transaminase; CHD, coronary heart disease; eGFR, estimated glomerular filtration rate; HFNC, high-flow nasal cannula; hsCRP, high sensitivity C-reactive protein; IMV, invasive
mechanical ventilation; IVIG, intravenous immunoglobulin; LDH, lactate dehydrogenase; NIMV, non-invasive mechanical ventilation; N/D, not determined; N/A not applicable; NT-proBNP, N terminal pro B type natriuretic peptide. Single/multiple refers to patients positive for a single aPL or positive for more than one aPLs but the values of all aPLs was <=40 CU. Multiple refers to patients positive for more than one aPLs and the value of at least one aPL was >40 CU. p value was calculated with a Kruskal-Wallis test followed by Dunnett's T2 test. For cerebral infarction during COVID-19 infection, p-value between aPLs negative group and multiple aPLs positive group was 0.023, p-value between aPLs single positive group and multiple aPLs positive group was 0.101.
| Antiphospholipid antibodies (aPLs) | Critically-ill (n=66) | Non-Critically-ill (n=13) |
|-----------------------------------|----------------------|--------------------------|
| Overall prevalence in any aPLs, n (%) | 31 (47.0) | 0 |
| IgA aCL, n (%) | 17 (25.8) | 0 |
| IgG aCL, n (%) | 4 (6.0) | 0 |
| IgM aCL, n (%) | 2 (3.0) | 0 |
| Lupus anticoagulant, n (%) | 2 (3.0) | 0 |
| IgA aβ2GP1, n (%) | 19 (28.8) | 0 |
| IgG aβ2GP1, n (%) | 12 (18.2) | 0 |
| IgM aβ2GP1, n (%) | 1 (1.5) | 0 |
| IgG aβ2GP1-D1, n (%) | 2 (3.0) | 0 |
| IgM aPS/PT, n (%) | 7 (10.6) | 0 |
| IgG aPS/PT, n (%) | 0 | 0 |
| IgA aCL+IgA aβ2GP1, n (%) | 15 (22.7) | 0 |
| IgM aCL+IgM aβ2GP1, n (%) | 1 (1.5) | 0 |
| IgA aβ2GP1+IgG aβ2GP1, n (%) | 1 (1.5) | 0 |
| LA+IgA aCL+IgA aβ2GP1, n (%) | 1 (1.5) | 0 |
| IgA aCL+IgA aβ2GP1+IgG aβ2GP1, n (%) | 10 (15.2) | 0 |
| IgA aCL+IgG aβ2GP1+IgM aCL, n (%) | 1 (1.5) | 0 |
| IgA aCL+IgA aβ2GP1+IgM aPS/PT, n (%) | 1 (1.5) | 0 |
| IgA aCL+IgG aCL+IgA aβ2GP1+IgG aβ2GP1, n (%) | 4 (6.1) | 0 |
| LA+IgA aCL+IgG aCL+IgA aβ2GP1+IgG aβ2GP1, n (%) | 1 (1.5) | 0 |

The cutoff values for positivity in all aPLs except IgM/IgG aPT/PS were set >20 U based on the recommendations of the manufacturer. The cutoff values for positivity in IgM/IgG aPT/PS were set >30 U based on the recommendations by the manufacturer. aβ2GP1, anti-β2-glycoprotein 1 antibodies; aβ2GP1-D1, anti-β2-glycoprotein domain 1 antibodies; aCL, anticardiolipin antibodies; aPS/PT, anti-phosphatidylserine/prothrombin; LA, lupus anticoagulants; N/D, not determined.
